ENGLEWOOD, Colo., April 6, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has been ranked 191 out of 500 on The Financial Times fourth annual list of The Americas' Fastest Growing Companies 2023.
"Zynex has consistently grown revenue and profitability over the last several years and we are pleased that our performance has been recognized alongside other innovative organizations," said Thomas Sandgaard, CEO and founder of Zynex. "The Company grew revenue by 308% and achieved a compound annual growth rate (CAGR) of 60% between 2018 and 2021, when the data for the rankings was collected. Additionally, we are pleased to be one of twenty-four publicly traded Healthcare & Life Sciences companies recognized in this high growth category."
The full list is available at: The Americas' Fastest Growing Companies 2023
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Gilmartin Group
Investor Relations Counsel
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$8.25 |
Daily Change: | -0.15 -1.79 |
Daily Volume: | 313,150 |
Market Cap: | US$262.760M |
December 12, 2024 December 05, 2024 October 24, 2024 September 04, 2024 September 03, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB